Dermatological adverse events under programmed cell death‐1 inhibitors as a prognostic marker in metastatic melanoma-Reference-Cited by-同舟云学术

Dermatological adverse events under programmed cell death‐1 inhibitors as a prognostic marker in metastatic melanoma

Published:2022-08-09 Issue:10 Volume:35 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Shreberk‐Hassidim Rony¹,Aizenbud Lilach²,Lussheimer Shalev³,Thomaidou Elena⁴^ORCID,Bdolah‐Abram Tali⁵,Merims Sharon⁶,Popovtzer Aron⁶,Maly Alex⁷,Lotem Michal⁶,Zlotogorski Abraham¹

Affiliation:

1. Department of Dermatology, Hadassah Medical Center Hebrew University of Jerusalem, The Faculty of Medicine Jerusalem Israel

2. Department of Medicine (Medical Oncology) Yale University School of Medicine New Haven Connecticut USA

3. Department of Internal Medicine E, Rabin Medical Center Beilinson Hospital Petah Tikva Israel

4. University of Nicosia Medical School Nicosia Cyprus

5. The Faculty of Medicine Hebrew University of Jerusalem Jerusalem Israel

6. Sharett Institute of Oncology, Hadassah Medical Center Hebrew University of Jerusalem, The Faculty of Medicine Jerusalem Israel

7. Department of Pathology, Hadassah Medical Center Hebrew University of Jerusalem, The Faculty of Medicine Jerusalem Israel

Publisher

Hindawi Limited

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.15747

Reference23 articles.

1. PD-1 and its ligands are important immune checkpoints in cancer

2. Immune checkpoint pathways: perspectives on myeloid malignancies

3. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

4. At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy

5. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the association between predictive factors and the development of immune‐related adverse events and prognostic factors for chemoimmunotherapy in patients with non‐small cell lung cancer: A multicenter retrospective study;Cancer Medicine;2024-08

2. Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment;JAMA Dermatology;2023-10-01

3. Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience;Frontiers in Medicine;2023-07-20

4. Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma;International Journal of Molecular Sciences;2022-12-11